Plan to Limit Medicare Coverage of Aduhelm Called ‘Not Patient-centered’

Home / Alzheimer's / Plan to Limit Medicare Coverage of Aduhelm Called ‘Not Patient-centered’
Plan to Limit Medicare Coverage of Aduhelm Called ‘Not Patient-centered’
February 10, 2022February 10, 2022
0

A recent proposal that Medicare only cover Aduhelm (aducanumab) for patients with Alzheimer’s disease who are enrolled in clinical trials is needlessly restrictive, and will prevent many people from accessing a medication that may be able to help them. That’s the argument made by Jeffrey Cummings, MD, a professor of brain health at the University of Nevada Las Vegas. Cummings’s paper, “Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision…

You must be logged in to read/download the full post.

The post Plan to Limit Medicare Coverage of Aduhelm Called ‘Not Patient-centered’ appeared first on BioNewsFeeds.